APA (7th ed.) Citation

K, K., JL, M., C, Y., HS, R., R, N., M, D., . . . LJ, E. (2024). Datopotamab-deruxtecan in early-stage breast cancer: The sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nature medicine, 30(12), 3728. https://doi.org/10.1038/s41591-024-03266-2

Chicago Style (17th ed.) Citation

K, Khoury, et al. "Datopotamab-deruxtecan in Early-stage Breast Cancer: The Sequential Multiple Assignment Randomized I-SPY2.2 Phase 2 Trial." Nature Medicine 30, no. 12 (2024): 3728. https://doi.org/10.1038/s41591-024-03266-2.

MLA (9th ed.) Citation

K, Khoury, et al. "Datopotamab-deruxtecan in Early-stage Breast Cancer: The Sequential Multiple Assignment Randomized I-SPY2.2 Phase 2 Trial." Nature Medicine, vol. 30, no. 12, 2024, p. 3728, https://doi.org/10.1038/s41591-024-03266-2.